Endocrinology

Cohosts Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, sit down with Darren McGuire, MD, to discuss the results of this groundbreaking trial.

This episode includes a breakdown of topline data from ATTAIN-1 and part 1 of the recap for ADCES 2025.

Despite obesity’s well-known influence on AF recurrence, neither comorbidity has a significant influence on outcomes from early rhythm control therapy.

Discover key advancements in endocrinology from July 2025, including FDA approvals and trial results.

Cafraglutide was effective with less frequent dosing than currently available medications that target GLP-1.

The once-daily oral GLP-1 RA met the primary endpoint for body weight reduction at 72 weeks and demonstrated improvements in cardiovascular risk factors.

Hosts offer perspective on the topline results from SURPASS-CVOT and what the cardiovascular data on tirzepatide means for care.

Tirzepatide was non-inferior to dulaglutide with an 8% lower rate of MACE-3 events while delivering greater reductions in A1C and weight.

Findings suggest 7000 steps per day is associated with a reduced risk of health outcomes including mortality, cardiovascular disease, and type 2 diabetes.

New data revealed that sleep impairment, especially daytime dysfunction, short duration, and sleep disturbances, is linked to increased diabetes distress.

The approval was based on positive results from the phase 3 foresiGHt trial and expands upon the indication for pediatric growth hormone deficiency.

A recent study has suggested the efficacy of a common type 2 diabetes treatment in improving cardiac structure and metabolic control.

Li and Shao discussed the T2D risk reduction seen over the course of the VA MOVE! lifestyle intervention program for veterans.

Isaacs and Bellini walk through the newly released Preexisting Diabetes in Pregnancy guidelines, discussing each of the 10 recommendations.

Findings showed GLP-1 RAs reduced the risk of overall dementia, particularly Alzheimer’s disease and non-vascular dementias, compared with metformin.

Presented at ENDO 2025, crinecerfont exhibited sustained androgen reduction when combined with glucocorticoids.

Isaacs and Bellini discuss the highlights of the Endocrine Society’s annual meeting, from upcoming treatments to public education.

An audio recap of the top 5 stories in healthcare news from the week of 07/07-07/13.

Isaacs, Bellini, and Levy discuss a currently recruiting trial investigating CGM metrics in pregnant individuals with type 1 diabetes.

Steger discussed the importance of tailoring diet strategies to patients with type 2 diabetes.

Shah discusses the stagnation of the T1D treatment landscape and the potential progress that GLP-1 RA research could present.

Philis-Tsimikas emphasized the impact of nonmedical factors on health and how clinicians can be cognizant of them in their patient management.

Shah discusses the results from the ADJUST-T1D trial comparing semaglutide to placebo, which saw a significant disparity in semaglutide’s favor.

Isaacs and Bellini discuss 3 more of the most impactful trials presented at the 85th annual American Diabetes Association conference in part 2 of this 2-part recap.

Isaacs and Bellini cover 3 of the most pivotal trial results from the 85th annual American Diabetes Association conference in part 1 of this 2-part recap.